false
0000310158
0000310158
2024-07-30
2024-07-30
0000310158
us-gaap:CommonStockMember
2024-07-30
2024-07-30
0000310158
mrk:Sec0.500NotesDue2024Member
2024-07-30
2024-07-30
0000310158
mrk:Sec1.875NotesDue2026Member
2024-07-30
2024-07-30
0000310158
mrk:Sec3.250NotesDue2032Member
2024-07-30
2024-07-30
0000310158
mrk:Sec2.500NotesDue2034Member
2024-07-30
2024-07-30
0000310158
mrk:Sec1.375NotesDue2036Member
2024-07-30
2024-07-30
0000310158
mrk:Sec3.500NotesDue2037Member
2024-07-30
2024-07-30
0000310158
mrk:Sec3.700NotesDue2044Member
2024-07-30
2024-07-30
0000310158
mrk:Sec3.750NotesDue2054Member
2024-07-30
2024-07-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported) July 30, 2024 (July
30, 2024)
Merck & Co., Inc.
(Exact name of registrant as specified in
its charter)
New Jersey (State or other jurisdiction of incorporation) | |
1-6571 (Commission File Number) | |
22-1918501 (I.R.S. Employer Identification No.) |
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices) | |
07065 (Zip Code) |
(Registrant’s telephone number, including
area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | |
Trading Symbol(s) | |
Name of each exchange on which registered |
| |
| |
|
Common
Stock ($0.50 par value) | |
MRK | |
New York Stock Exchange |
0.500% Notes due 2024 | |
MRK 24 | |
New York Stock Exchange |
1.875% Notes due 2026 | |
MRK/26 | |
New York Stock Exchange |
3.250% Notes due 2032 | |
MRK/32 | |
New York Stock Exchange |
2.500% Notes due 2034 | |
MRK/34 | |
New York Stock Exchange |
1.375% Notes due 2036 | |
MRK 36A | |
New York Stock Exchange |
3.500% Notes due 2037 | |
MRK/37 | |
New York Stock Exchange |
3.700% Notes due 2044 | |
MRK/44 | |
New York Stock Exchange |
3.750% Notes due 2054 | |
MRK/54 | |
New York Stock Exchange |
Item
2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being
furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued
by Merck & Co., Inc. on July 30, 2024, regarding earnings for the second quarter of 2024, attached as Exhibit 99.1.
Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Merck & Co., Inc. |
|
Date: July 30, 2024 |
By: |
/s/ Kelly E. W. Grez |
|
|
Kelly E. W. Grez |
|
|
Corporate Secretary |
Exhibit 99.1
|
News Release |
|
|
Merck Announces Second-Quarter 2024 Financial
Results
| - | Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth
Was 11% |
| - | KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% |
| - | GAAP EPS Was $2.14; Non-GAAP EPS Was $2.28 |
| - | Successful Initial Launch of WINREVAIR in the U.S.; Received Positive EU CHMP Opinion for Adults With PAH |
| - | Achieved Key Milestones in Vaccine Programs |
| o | Following FDA Approval, CAPVAXIVE Unanimously Recommended by the CDC’s ACIP for Pneumococcal Vaccination for Certain Adults |
| o | Announced Positive Results From Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody
for Infants |
| - | Completed Acquisitions of EyeBio and Elanco’s Aqua Business in July 2024 |
| - | Full-Year 2024 Financial Outlook |
| o | Raises and Narrows Expected Worldwide Sales Range To Be Between $63.4 Billion and $64.4 Billion |
| o | Now Expects Non-GAAP EPS To Be Between $7.94 and $8.04; Outlook Reflects Negative Impact From One-Time Charge of Approximately $1.3
Billion, or $0.51 per Share, for the Acquisition of EyeBio |
RAHWAY, N.J.,
July 30, 2024 – Merck (NYSE: MRK), known as MSD outside the United
States and Canada, today announced financial results for the second quarter of 2024.
“Our business is demonstrating strong momentum
as we exit the first half of the year,” said Robert M. Davis, chairman and chief executive officer, Merck. “Through excellent
scientific, commercial and operational execution, we’re achieving significant milestones for our company and for patients, including
the launch of WINREVAIR. I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as
we continue delivering innovation that solves unmet medical needs.”
Financial Summary
| |
Second Quarter | |
$ in millions, except EPS amounts | |
2024 | | |
2023 | | |
Change | | |
Change Ex- Exchange | |
Sales | |
$ | 16,112 | | |
$ | 15,035 | | |
| 7 | % | |
| 11 | % |
GAAP net income (loss)1 | |
| 5,455 | | |
| (5,975 | ) | |
| N/M | | |
| N/M | |
Non-GAAP net income (loss) that excludes certain items1,2* | |
| 5,809 | | |
| (5,220 | ) | |
| N/M | | |
| N/M | |
GAAP EPS | |
| 2.14 | | |
| (2.35 | ) | |
| N/M | | |
| N/M | |
Non-GAAP EPS that excludes certain items2* | |
| 2.28 | | |
| (2.06 | ) | |
| N/M | | |
| N/M | |
*Refer to table on page 7.
N/M – Not meaningful
For the second quarter of 2024, Generally Accepted
Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.14 and non-GAAP EPS was $2.28. GAAP and non-GAAP loss per
share for the second quarter of 2023 include a charge of $4.02 per share for the acquisition of Prometheus Biosciences, Inc. (Prometheus).
Non-GAAP EPS in both periods excludes acquisition- and divestiture-related costs, costs related to restructuring programs, as well as
income and losses from investments in equity securities. Non-GAAP EPS in the second quarter of 2024 also excludes a tax benefit due to
a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments
related to the 2019 federal tax return year.
Year-to-date results can be found in the attached
tables.
1 Net income (loss) attributable
to Merck & Co., Inc.
2 Merck is providing certain 2024 and 2023 non-GAAP information
that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance
and trends. Management believes that providing this information enhances investors’ understanding of the company’s results
because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting
purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including
senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered
in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.
Second-Quarter Sales Performance
The following table reflects sales of the company’s
top products and significant performance drivers.
| |
Second Quarter |
$ in millions | |
2024 | | |
2023 | | |
Change | | |
Change Ex- Exchange | | |
Commentary |
Total Sales | |
$ | 16,112 | | |
$ | 15,035 | | |
| 7 | % | |
| 11 | % | |
Approximately 2 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. |
Pharmaceutical | |
| 14,408 | | |
| 13,457 | | |
| 7 | % | |
| 11 | % | |
Increase driven by growth in oncology, cardiovascular and vaccines, partially offset by declines in diabetes and virology. |
KEYTRUDA | |
| 7,270 | | |
| 6,271 | | |
| 16 | % | |
| 21 | % | |
Growth driven by increased global uptake in earlier-stage indications, including triple-negative breast cancer (TNBC) and renal cell carcinoma, as well as non-small cell lung cancer in the U.S., and continued strong global demand from metastatic indications. Approximately 4 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. |
GARDASIL/GARDASIL 9 | |
| 2,478 | | |
| 2,458 | | |
| 1 | % | |
| 4 | % | |
Growth primarily due to higher sales in the U.S. driven by higher pricing, demand and public-sector buying patterns, as well as higher demand in certain ex-U.S. markets. Growth was largely offset by lower sales in China due to timing of shipments compared with prior year. |
JANUVIA/JANUMET | |
| 629 | | |
| 864 | | |
| -27 | % | |
| -23 | % | |
Decline primarily due to lower pricing and demand in the U.S., as well as ongoing generic competition in many international markets, particularly in Europe and the Asia Pacific region. |
PROQUAD, M-M-R II and VARIVAX | |
| 617 | | |
| 582 | | |
| 6 | % | |
| 7 | % | |
Growth largely from higher pricing and demand in the U.S. |
BRIDION | |
| 455 | | |
| 502 | | |
| -9 | % | |
| -8 | % | |
Decline primarily due to generic competition in certain ex-U.S. markets, particularly in Europe and the Asia Pacific region, partially offset by higher demand in the U.S. |
Lynparza* | |
| 317 | | |
| 310 | | |
| 2 | % | |
| 4 | % | |
Growth due to higher demand in the U.S. and certain international markets, particularly in China and Europe. |
Lenvima* | |
| 249 | | |
| 242 | | |
| 3 | % | |
| 4 | % | |
Growth primarily from higher demand in the U.S. |
VAXNEUVANCE | |
| 189 | | |
| 168 | | |
| 13 | % | |
| 16 | % | |
Growth largely driven by continued uptake from launches in Japan and Europe, partially offset by lower demand and public-sector buying patterns in the U.S. |
PREVYMIS | |
| 188 | | |
| 143 | | |
| 31 | % | |
| 35 | % | |
Growth primarily due to higher global demand, particularly in the U.S., China and Europe. |
ROTATEQ | |
| 163 | | |
| 131 | | |
| 25 | % | |
| 26 | % | |
Growth primarily due to timing of shipments to China and public-sector buying patterns in the U.S., partially offset by lower demand in the U.S. |
WELIREG | |
| 126 | | |
| 50 | | |
| 150 | % | |
| 150 | % | |
Growth primarily driven by higher demand in the U.S., largely attributable to launch of a new indication. |
LAGEVRIO | |
| 110 | | |
| 203 | | |
| -46 | % | |
| -42 | % | |
Decline due to lower demand and pricing in certain markets in the Asia Pacific region, partially offset by higher demand in Japan and the U.S. |
WINREVAIR | |
| 70 | | |
| - | | |
| - | | |
| - | | |
Represents sales in the U.S. following approval in March 2024. About 40% of sales were attributable to doses administered to patients and remainder was due to distributors building inventory in support of increasing demand. |
Animal Health | |
| 1,482 | | |
| 1,456 | | |
| 2 | % | |
| 6 | % | |
Growth primarily driven by higher pricing in both Livestock and Companion Animal product portfolios, as well as higher demand for Livestock products, partially offset by a decline in Companion Animal distributor inventory. Approximately 3 percentage points of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. |
Livestock | |
| 837 | | |
| 807 | | |
| 4 | % | |
| 11 | % | |
Growth primarily driven by higher demand for ruminant and poultry products, as well as higher pricing across product portfolio. |
Companion Animal | |
| 645 | | |
| 649 | | |
| -1 | % | |
| 1 | % | |
Sales were relatively flat compared with prior year reflecting lower distributor inventory, largely offset by higher pricing across product portfolio. Sales of BRAVECTO were $331 million and $326 million in current and prior-year quarters, respectively, which represented growth of 2%, or 3% excluding impact of foreign exchange. |
Other Revenues** | |
| 222 | | |
| 122 | | |
| 82 | % | |
| 53 | % | |
Growth primarily due to higher royalty income and favorable impact of revenue hedging activities. |
*Alliance revenue for this product represents Merck’s
share of profits, which are product sales net of cost of sales and commercialization costs.
**Other revenues are comprised primarily of revenues
from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue hedging activities.
Second-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions | |
GAAP | | |
Acquisition- and Divestiture- Related
Costs3 | | |
Restructuring Costs | | |
(Income) Loss From Investments in Equity Securities | | |
Non- GAAP2 | |
Second Quarter 2024 | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
$ | 3,745 | | |
$ | 606 | | |
$ | 66 | | |
$ | - | | |
$ | 3,073 | |
Selling, general and administrative | |
| 2,739 | | |
| 24 | | |
| 31 | | |
| - | | |
| 2,684 | |
Research and development | |
| 3,500 | | |
| 20 | | |
| - | | |
| - | | |
| 3,480 | |
Restructuring costs | |
| 80 | | |
| - | | |
| 80 | | |
| - | | |
| - | |
Other (income) expense, net | |
| 42 | | |
| (17 | ) | |
| - | | |
| (49 | ) | |
| 108 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Second Quarter 2023 | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
$ | 4,024 | | |
$ | 467 | | |
$ | 32 | | |
$ | - | | |
$ | 3,525 | |
Selling, general and administrative | |
| 2,702 | | |
| 25 | | |
| 52 | | |
| - | | |
| 2,625 | |
Research and development | |
| 13,321 | | |
| 9 | | |
| 1 | | |
| - | | |
| 13,311 | |
Restructuring costs | |
| 151 | | |
| - | | |
| 151 | | |
| - | | |
| - | |
Other (income) expense, net | |
| 172 | | |
| (3 | ) | |
| - | | |
| 194 | | |
| (19 | ) |
GAAP Expense, EPS and Related Information
Gross margin was 76.8% for the second quarter of
2024 compared with 73.2% for the second quarter of 2023. The increase was primarily due to the favorable impact of product mix (including
lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), partially offset by higher amortization of intangible assets.
Selling, general and administrative (SG&A)
expenses were $2.7 billion in the second quarter of 2024, an increase of 1% compared with the second quarter of 2023. The increase was
primarily due to higher administrative and promotional costs, largely offset by the favorable impact of foreign exchange and lower restructuring
costs.
Research and development (R&D) expenses were
$3.5 billion in the second quarter of 2024 compared with $13.3 billion in the second quarter of 2023. The decrease was primarily due to
a $10.2 billion charge in the second quarter of 2023 for the acquisition of Prometheus, partially offset by higher clinical development
spending and increased compensation and benefit costs.
Other (income) expense, net, was $42 million of
expense in the second quarter of 2024 compared with $172 million of expense in the second quarter of 2023. The decrease was primarily
due to income from investments in equity securities in 2024 compared with losses in 2023, partially offset by higher net interest expense
in 2024.
| 3 | Reflects expenses related to acquisitions of businesses, including
the amortization of intangible assets, intangible asset impairment charges and expense or income related to changes in the estimated
fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs associated
with acquisitions and divestitures, as well as amortization of intangible assets related to collaborations and licensing arrangements. |
The effective tax rate of 9.1% for the second quarter
of 2024 includes a 4.3 percentage point favorable impact due to a reduction in reserves for unrecognized income tax benefits, resulting
from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
GAAP EPS was $2.14 for the second quarter of 2024
compared with GAAP loss per share of $2.35 for the second quarter of 2023. GAAP loss per share in the second quarter of 2023 includes
a charge of $4.02 per share for the acquisition of Prometheus.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 80.9% for the second
quarter of 2024 compared with 76.6% for the second quarter of 2023. The increase was primarily due to the favorable impact of product
mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9).
Non-GAAP SG&A expenses were $2.7 billion in
the second quarter of 2024, an increase of 2% compared with the second quarter of 2023. The increase was primarily due to higher administrative
and promotional costs, largely offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $3.5 billion in
the second quarter of 2024 compared with $13.3 billion in the second quarter of 2023. The decrease was primarily due to a $10.2 billion
charge in the second quarter of 2023 for the acquisition of Prometheus, partially offset by higher clinical development spending and increased
compensation and benefit costs.
Non-GAAP other (income) expense, net, was $108
million of expense in the second quarter of 2024 compared with $19 million of income in the second quarter of 2023, primarily due to higher
net interest expense.
The non-GAAP effective tax rate was 14.1% for the
second quarter of 2024.
Non-GAAP EPS was $2.28 for the second quarter of
2024 compared with non-GAAP loss per share of $2.06 for the second quarter of 2023. Non-GAAP loss per share in the second quarter of 2023
includes a charge of $4.02 per share for the acquisition of Prometheus.
A reconciliation of GAAP to non-GAAP net income
(loss) and EPS is provided in the table that follows.
| |
Second Quarter | |
$ in millions, except EPS amounts | |
2024 | | |
2023 | |
EPS | |
| | | |
| | |
GAAP EPS | |
$ | 2.14 | | |
$ | (2.35 | ) |
Difference | |
| 0.14 | | |
| 0.29 | |
Non-GAAP EPS that excludes items listed below2 | |
$ | 2.28 | | |
$ | (2.06 | ) |
| |
| | | |
| | |
Net Income (Loss) | |
| | | |
| | |
GAAP net income (loss)1 | |
$ | 5,455 | | |
$ | (5,975 | ) |
Difference | |
| 354 | | |
| 755 | |
Non-GAAP net income (loss) that excludes items listed below1,2 | |
$ | 5,809 | | |
$ | (5,220 | ) |
| |
| | | |
| | |
Excluded Items: | |
| | | |
| | |
Acquisition- and divestiture-related costs3 | |
$ | 633 | | |
$ | 498 | |
Restructuring costs | |
| 177 | | |
| 236 | |
(Income) loss from investments in equity securities | |
| (49 | ) | |
| 194 | |
Decrease to net income/increase to net loss before taxes | |
| 761 | | |
| 928 | |
Income tax (benefit) expense4 | |
| (407 | ) | |
| (173 | ) |
Decrease to net income/increase to net loss | |
$ | 354 | | |
$ | 755 | |
Pipeline and Portfolio Highlights
In the second quarter, Merck demonstrated further
progress in its strong and diverse pipeline, achieving multiple regulatory and clinical milestones.
In vaccines, Merck recently received approval from
the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, now the first pneumococcal conjugate vaccine specifically designed to address
the serotypes responsible for approximately 85% of invasive pneumococcal disease cases in adults age 65 and older, based on the U.S. Centers
for Disease Control and Prevention (CDC) data from 2018-2021. The CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously
voted to recommend CAPVAXIVE for adults age 65 and older who have not received a pneumococcal conjugate vaccine or whose vaccination history
is unknown, for adults 19 to 64 with certain risk conditions, and for adults 19 and older who have started their pneumococcal vaccine
series with PCV13. Additionally, shared clinical decision-making is recommended for a supplemental dose of CAPVAXIVE for adults over 65
who completed their vaccine series with both PCV13 and PPSV23.
The company also recently announced positive topline
results from its Phase 2b/3 trial of clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative monoclonal
antibody for infants, which met all primary safety and efficacy endpoints.
In cardiometabolic disease, Merck continued to
make progress in its launch of WINREVAIR in the U.S. As of the end of June, more than 1,000 patients have received WINREVAIR. The company
also announced that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for
WINREVAIR. If approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor therapy for pulmonary arterial
hypertension (PAH, World Health Organization [WHO] Group 1) to be approved in Europe, offering a new treatment option for certain adults
with this rare, progressive disease. Additional worldwide regulatory filings for WINREVAIR are underway.
4 Represents the estimated tax impacts on the reconciling
items based on applying the statutory rate of the originating territory of the non-GAAP adjustments, as well as a $259 million benefit
in the second quarter of 2024, due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the
statute of limitations for assessments related to the 2019 federal tax return year.
In oncology, Merck received FDA approval for KEYTRUDA
in combination with chemotherapy, followed by KEYTRUDA as a single agent, for the treatment of certain patients with endometrial carcinoma.
This marks the 40th indication for KEYTRUDA in the U.S., reinforcing its importance as a foundational therapy for certain types
of cancer.
At the 2024 American Society of Clinical Oncology
Annual Meeting, new data were presented on four approved oncology medicines and four pipeline candidates in more than 25 types of cancer.
In collaboration with Moderna, Inc., Merck announced encouraging three-year follow-up data for V940 (mRNA-4157) in combination with KEYTRUDA
for the adjuvant treatment of patients with high-risk stage III and IV melanoma following complete resection. In addition, new Phase 3
data from a study conducted in China and independently led by Kelun-Biotech evaluating sacituzumab tirumotecan (MK-2870/SKB264), an investigational
anti-TROP2 antibody-drug conjugate being developed by Merck in collaboration with Kelun-Biotech, were presented in previously treated
patients with locally recurrent or metastatic TNBC.
Merck Animal Health launched the 12-month injectable
formulation of BRAVECTO for use in dogs in a number of markets in Europe for the treatment and persistent killing of fleas (Ctenocephalides
felis and Ctenocephalides canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, Ixodes hexagonus, and Dermacentor reticulatus).
In addition, in July 2024, Merck completed the acquisition of the aqua business of Elanco Animal Health Incorporated.
In July 2024, Merck also completed the acquisition
of Eyebiotech Limited (EyeBio), which includes the lead candidate Restoret™/MK-3000 that is being evaluated for the treatment of
patients with certain retinal diseases, including diabetic macular edema and neovascular age-related macular degeneration, as well as
preclinical candidates. And, Merck and Orion Corporation announced the mutual exercise of an option to convert the companies’ ongoing
co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates,
into an exclusive global license for Merck.
Notable recent news releases on Merck’s pipeline
and portfolio are provided in the table that follows.
Oncology |
FDA Approved KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma, Based on Results From Phase 3 NRG-GY018/KEYNOTE-868 Trial |
(Read Announcement) |
FDA Granted Priority Review to Merck’s Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma, Based on Results From Phase 3 KEYNOTE-483 Trial; FDA Set Prescription Drug User Fee Act (PDUFA) Date of Sept. 25, 2024 |
(Read Announcement) |
Merck Received Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma, Based on Results From Phase 3 KEYNOTE-A39/EV-302 Trial |
(Read Announcement) |
Moderna and Merck Announced Three-Year Data for mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated Sustained Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection |
(Read Announcement) |
Merck Announced Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage TNBC |
(Read Announcement) |
Merck Announced Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
(Read Announcement) |
Patritumab Deruxtecan Biologics License Application Submission Received Complete Response Letter From FDA Due to Inspection Findings at Third-Party Manufacturer |
(Read Announcement) |
Vaccines |
FDA Approved CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults, Based on Results From Four Phase 3 Trials |
(Read Announcement) |
CDC’s ACIP Unanimously Recommended CAPVAXIVE for Pneumococcal Vaccination in Appropriate Adults |
(Read Announcement) |
Merck Announced Topline Results From Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants, Met All Primary Safety and Efficacy Endpoints |
(Read Announcement) |
Cardiometabolic |
Merck Received Positive EU CHMP Opinion for WINREVAIR (sotatercept) in PAH |
(Read Announcement) |
Full-Year 2024 Financial Outlook
The following table summarizes the company’s
full-year financial outlook.
| |
Full Year 2024 |
| |
Updated | |
Prior |
Sales* | |
$63.4 to $64.4 billion | |
$63.1 to $64.3 billion |
Non-GAAP Gross margin2 | |
Approximately 81% | |
Approximately 81% |
Non-GAAP Operating expenses2** | |
$26.8 to $27.6 billion | |
$25.2 to $26.1 billion |
Non-GAAP Other (income) expense, net2 | |
Approximately $350 million expense | |
Approximately $250 million expense |
Non-GAAP Effective tax rate2 | |
15.5% to 16.5% | |
14.5% to 15.5% |
Non-GAAP EPS2*** | |
$7.94 to $8.04 | |
$8.53 to $8.65 |
Share count (assuming dilution) | |
Approximately 2.54 billion | |
Approximately 2.55 billion |
*The company does not have any non-GAAP adjustments
to sales.
**Includes one-time R&D charges of $656 million
for Harpoon Therapeutics, Inc. (Harpoon) acquisition and $1.3 billion for EyeBio acquisition. Outlook does not assume any additional significant
potential business development transactions.
***Includes one-time charges totaling $0.77 per
share for the Harpoon and EyeBio acquisitions.
Merck has not provided a reconciliation of forward-looking
non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax rate and non-GAAP EPS
to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation,
including intangible asset impairment charges, legal settlements, and gains and losses from investments in equity securities either owned
directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the company’s future GAAP results.
Merck continues to experience strong global demand
for key growth products, particularly in oncology, and despite impacts related to the lower sell out of GARDASIL from Zhifei Biological
Products Co., Ltd. (the company’s distributor and commercialization partner in China) into the points of vaccination in the market
during the quarter, Merck is raising and narrowing its full-year sales outlook.
Merck now expects its full-year sales to be between
$63.4 billion and $64.4 billion, including a negative impact of foreign exchange of approximately 3 percentage points, at mid-July 2024
exchange rates. Approximately 2 percentage points of the negative impact of foreign exchange is due to the devaluation of the Argentine
peso, which the company expects will largely be offset by inflation-related price increases, consistent with practice in that market.
Merck now expects its full-year non-GAAP effective
income tax rate to be between 15.5% and 16.5%, which includes an unfavorable impact related to the one-time charge for the acquisition
of EyeBio, which is not tax deductible.
Merck now expects its full-year non-GAAP EPS to
be between $7.94 and $8.04, including one-time charges of $0.26 and $0.51 per share for the acquisitions of Harpoon and EyeBio, respectively.
The outlook includes a negative impact of foreign exchange of more than $0.30 per share. The negative impact of foreign exchange is primarily
due to the devaluation of the Argentine peso, which the company expects will largely be offset by inflation-related price increases, consistent
with practice in that market. This revised non-GAAP EPS range reflects the following items, which were not previously included in the
outlook:
| · | A charge of $1.3 billion, or $0.51 per share, for the acquisition of EyeBio. |
| · | Estimated 2024 expense of approximately $0.09 per share to be incurred to
finance the EyeBio and Elanco aqua business acquisitions and to advance the acquired assets. |
Consistent with past practice, the financial outlook
does not assume additional significant potential business development transactions.
Non-GAAP EPS excludes acquisition- and divestiture-related
costs, costs related to restructuring programs, income and losses from investments in equity securities, as well as a tax benefit in 2024
due to a reduction in reserves for unrecognized income tax benefits, resulting from the expiration of the statute of limitations for assessments
related to the 2019 federal tax return year.
Earnings Conference Call
Investors, journalists and the general public may
access a live audio webcast of the earnings conference call on Tuesday, July 30, at 9 a.m. ET via this weblink. A replay of the webcast,
along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available
at www.merck.com.
All participants may join the call by dialing (800)
779-0641 (U.S. and Canada Toll-Free) or (517) 308-9147 and using the access code 4761229.
About Merck
At Merck, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For
more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global
workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more
information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J.,
USA
This news release of Merck & Co., Inc., Rahway,
N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of
the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline
candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.
If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited
to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward
health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s
patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC)
available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11,
16 and 18] Vaccine, Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine
Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: |
Investor Contacts: |
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com |
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com |
MERCK
& CO., INC. |
CONSOLIDATED
STATEMENT OF OPERATIONS - GAAP |
(AMOUNTS
IN MILLIONS, EXCEPT PER SHARE FIGURES) |
(UNAUDITED) |
Table
1 |
| |
GAAP | | |
| | |
GAAP | | |
| |
| |
| | |
| | |
June YTD | | |
June YTD | | |
| |
| |
2Q24 | | |
2Q23 | | |
%
Change | | |
2024 | | |
2023 | | |
%
Change | |
Sales | |
$ | 16,112 | | |
$ | 15,035 | | |
| 7 | % | |
$ | 31,887 | | |
$ | 29,522 | | |
| 8 | % |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Costs, Expenses
and Other | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
| 3,745 | | |
| 4,024 | | |
| -7 | % | |
| 7,285 | | |
| 7,951 | | |
| -8 | % |
Selling, general and administrative | |
| 2,739 | | |
| 2,702 | | |
| 1 | % | |
| 5,221 | | |
| 5,182 | | |
| 1 | % |
Research and development | |
| 3,500 | | |
| 13,321 | | |
| -74 | % | |
| 7,492 | | |
| 17,597 | | |
| -57 | % |
Restructuring costs | |
| 80 | | |
| 151 | | |
| -47 | % | |
| 202 | | |
| 218 | | |
| -7 | % |
Other (income) expense, net | |
| 42 | | |
| 172 | | |
| -76 | % | |
| 12 | | |
| 259 | | |
| -95 | % |
Income (Loss) Before Taxes | |
| 6,006 | | |
| (5,335 | ) | |
| * | | |
| 11,675 | | |
| (1,685 | ) | |
| *
| |
Income Tax Provision | |
| 545 | | |
| 637 | | |
| | | |
| 1,447 | | |
| 1,462 | | |
| | |
Net Income (Loss) | |
| 5,461 | | |
| (5,972 | ) | |
| * | | |
| 10,228 | | |
| (3,147 | ) | |
| *
| |
Less: Net Income Attributable
to Noncontrolling Interests | |
| 6 | | |
| 3 | | |
| | | |
| 11 | | |
| 7 | | |
| | |
Net Income (Loss) Attributable
to Merck & Co., Inc. | |
$ | 5,455 | | |
$ | (5,975 | ) | |
| * | | |
$ | 10,217 | | |
$ | (3,154 | ) | |
| *
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Earnings
(Loss) per Common Share Assuming Dilution (1) | |
$ | 2.14 | | |
$ | (2.35 | ) | |
| * | | |
$ | 4.02 | | |
$ | (1.24 | ) | |
| *
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Average
Shares Outstanding Assuming Dilution (1) | |
| 2,544 | | |
| 2,539 | | |
| | | |
| 2,544 | | |
| 2,539 | | |
| | |
Tax Rate | |
| 9.1 | % | |
| -11.9 | % | |
| | | |
| 12.4 | % | |
| -86.8 | % | |
| | |
* 100% or greater
(1) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.
MERCK
& CO., INC. |
THREE
AND SIX MONTHS ENDED JUNE 30, 2024 GAAP TO NON-GAAP RECONCILIATION |
(AMOUNTS
IN MILLIONS, EXCEPT PER SHARE FIGURES) |
(UNAUDITED) |
Table
2a |
|
|
GAAP |
|
|
Acquisition
and
Divestiture-
Related
Costs (1) |
|
|
Restructuring
Costs (2) |
|
|
(Income)
Loss from
Investments
in Equity
Securities |
|
|
Certain
Other
Items |
|
|
Adjustment
Subtotal |
|
|
Non-GAAP |
|
Second Quarter |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
$ |
3,745 |
|
|
|
606 |
|
|
|
66 |
|
|
|
|
|
|
|
|
|
|
|
672 |
|
|
$ |
3,073 |
|
Selling, general and administrative |
|
|
2,739 |
|
|
|
24 |
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
55 |
|
|
|
2,684 |
|
Research and development |
|
|
3,500 |
|
|
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20 |
|
|
|
3,480 |
|
Restructuring costs |
|
|
80 |
|
|
|
|
|
|
|
80 |
|
|
|
|
|
|
|
|
|
|
|
80 |
|
|
|
– |
|
Other (income) expense, net |
|
|
42 |
|
|
|
(17 |
) |
|
|
|
|
|
|
(49 |
) |
|
|
|
|
|
|
(66 |
) |
|
|
108 |
|
Income Before Taxes |
|
|
6,006 |
|
|
|
(633 |
) |
|
|
(177 |
) |
|
|
49 |
|
|
|
|
|
|
|
(761 |
) |
|
|
6,767 |
|
Income Tax Provision (Benefit) |
|
|
545 |
|
|
|
(129 |
)(3) |
|
|
(30 |
)(3) |
|
|
11 |
(3) |
|
|
(259 |
)(4) |
|
|
(407 |
) |
|
|
952 |
|
Net Income |
|
|
5,461 |
|
|
|
(504 |
) |
|
|
(147 |
) |
|
|
38 |
|
|
|
259 |
|
|
|
(354 |
) |
|
|
5,815 |
|
Net Income Attributable to Merck & Co., Inc. |
|
|
5,455 |
|
|
|
(504 |
) |
|
|
(147 |
) |
|
|
38 |
|
|
|
259 |
|
|
|
(354 |
) |
|
|
5,809 |
|
Earnings per Common Share Assuming Dilution |
|
$ |
2.14 |
|
|
|
(0.20 |
) |
|
|
(0.06 |
) |
|
|
0.02 |
|
|
|
0.10 |
|
|
|
(0.14 |
) |
|
$ |
2.28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax Rate |
|
|
9.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June YTD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
$ |
7,285 |
|
|
|
1,069 |
|
|
|
182 |
|
|
|
|
|
|
|
|
|
|
|
1,251 |
|
|
$ |
6,034 |
|
Selling, general and administrative |
|
|
5,221 |
|
|
|
45 |
|
|
|
36 |
|
|
|
|
|
|
|
|
|
|
|
81 |
|
|
|
5,140 |
|
Research and development |
|
|
7,492 |
|
|
|
36 |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
38 |
|
|
|
7,454 |
|
Restructuring costs |
|
|
202 |
|
|
|
|
|
|
|
202 |
|
|
|
|
|
|
|
|
|
|
|
202 |
|
|
|
– |
|
Other (income) expense, net |
|
|
12 |
|
|
|
(21 |
) |
|
|
|
|
|
|
(165 |
) |
|
|
|
|
|
|
(186 |
) |
|
|
198 |
|
Income Before Taxes |
|
|
11,675 |
|
|
|
(1,129 |
) |
|
|
(422 |
) |
|
|
165 |
|
|
|
|
|
|
|
(1,386 |
) |
|
|
13,061 |
|
Income Tax Provision (Benefit) |
|
|
1,447 |
|
|
|
(221 |
)(3) |
|
|
(72 |
)(3) |
|
|
36 |
(3) |
|
|
(259 |
)(4) |
|
|
(516 |
) |
|
|
1,963 |
|
Net Income |
|
|
10,228 |
|
|
|
(908 |
) |
|
|
(350 |
) |
|
|
129 |
|
|
|
259 |
|
|
|
(870 |
) |
|
|
11,098 |
|
Net Income Attributable to Merck & Co., Inc. |
|
|
10,217 |
|
|
|
(908 |
) |
|
|
(350 |
) |
|
|
129 |
|
|
|
259 |
|
|
|
(870 |
) |
|
|
11,087 |
|
Earnings per Common Share Assuming Dilution |
|
$ |
4.02 |
|
|
|
(0.35 |
) |
|
|
(0.14 |
) |
|
|
0.05 |
|
|
|
0.10 |
|
|
|
(0.34 |
) |
|
$ |
4.36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax Rate |
|
|
12.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.0 |
% |
Only
the line items that are affected by non-GAAP adjustments are shown. |
|
Merck
is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have
on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’
understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics.
In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP
pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior
to, information prepared in accordance with GAAP. |
|
(1)
Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in
selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts
included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur
MSD joint venture. |
(2)
Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or
divested related to activities under the company's formal restructuring programs. |
(3)
Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory
of the non-GAAP adjustments. |
(4)
Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the
statute of limitations for assessments related to the 2019 federal tax return year. |
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table
3
| |
| 2024 | | |
| 2023 | | |
| 2Q | | |
| June YTD | |
| |
1Q | | |
| 2Q | | |
| June YTD | | |
| 1Q | | |
| 2Q | | |
| June YTD | | |
| 3Q | | |
| 4Q | | |
| Full
Year | | |
| Nom
% | | |
| Ex-Exch
% | | |
| Nom
% | | |
| Ex-Exch
% | |
TOTAL
SALES (1) | |
$ | 15,775 | | |
$ | 16,112 | | |
$ | 31,887 | | |
$ | 14,487 | | |
$ | 15,035 | | |
$ | 29,522 | | |
$ | 15,962 | | |
$ | 14,630 | | |
$ | 60,115 | | |
| 7 | | |
| 11 | | |
| 8 | | |
| 11 | |
PHARMACEUTICAL | |
| 14,006 | | |
| 14,408 | | |
| 28,415 | | |
| 12,721 | | |
| 13,457 | | |
| 26,179 | | |
| 14,263 | | |
| 13,141 | | |
| 53,583 | | |
| 7 | | |
| 11 | | |
| 9 | | |
| 12 | |
Oncology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Keytruda | |
| 6,947 | | |
| 7,270 | | |
| 14,217 | | |
| 5,795 | | |
| 6,271 | | |
| 12,065 | | |
| 6,338 | | |
| 6,608 | | |
| 25,011 | | |
| 16 | | |
| 21 | | |
| 18 | | |
| 22 | |
Alliance
Revenue – Lynparza (2) | |
| 292 | | |
| 317 | | |
| 609 | | |
| 275 | | |
| 310 | | |
| 585 | | |
| 299 | | |
| 315 | | |
| 1,199 | | |
| 2 | | |
| 4 | | |
| 4 | | |
| 6 | |
Alliance
Revenue – Lenvima (2) | |
| 255 | | |
| 249 | | |
| 504 | | |
| 232 | | |
| 242 | | |
| 474 | | |
| 260 | | |
| 226 | | |
| 960 | | |
| 3 | | |
| 4 | | |
| 6 | | |
| 7 | |
Welireg | |
| 85 | | |
| 126 | | |
| 211 | | |
| 42 | | |
| 50 | | |
| 92 | | |
| 54 | | |
| 72 | | |
| 218 | | |
| 150 | | |
| 150 | | |
| 128 | | |
| 128 | |
Alliance
Revenue – Reblozyl (3) | |
| 71 | | |
| 90 | | |
| 161 | | |
| 43 | | |
| 47 | | |
| 90 | | |
| 52 | | |
| 70 | | |
| 212 | | |
| 92 | | |
| 92 | | |
| 80 | | |
| 80 | |
Vaccines
(4) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gardasil/Gardasil 9 | |
| 2,249 | | |
| 2,478 | | |
| 4,727 | | |
| 1,972 | | |
| 2,458 | | |
| 4,430 | | |
| 2,585 | | |
| 1,871 | | |
| 8,886 | | |
| 1 | | |
| 4 | | |
| 7 | | |
| 10 | |
ProQuad/M-M-R II/Varivax | |
| 570 | | |
| 617 | | |
| 1,187 | | |
| 528 | | |
| 582 | | |
| 1,109 | | |
| 713 | | |
| 545 | | |
| 2,368 | | |
| 6 | | |
| 7 | | |
| 7 | | |
| 7 | |
Vaxneuvance | |
| 219 | | |
| 189 | | |
| 408 | | |
| 106 | | |
| 168 | | |
| 274 | | |
| 214 | | |
| 176 | | |
| 665 | | |
| 13 | | |
| 16 | | |
| 49 | | |
| 51 | |
RotaTeq | |
| 216 | | |
| 163 | | |
| 379 | | |
| 297 | | |
| 131 | | |
| 428 | | |
| 156 | | |
| 185 | | |
| 769 | | |
| 25 | | |
| 26 | | |
| -11 | | |
| -10 | |
Pneumovax 23 | |
| 61 | | |
| 59 | | |
| 120 | | |
| 96 | | |
| 92 | | |
| 188 | | |
| 140 | | |
| 85 | | |
| 412 | | |
| -36 | | |
| -32 | | |
| -36 | | |
| -32 | |
Hospital Acute Care | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Bridion | |
| 440 | | |
| 455 | | |
| 895 | | |
| 487 | | |
| 502 | | |
| 989 | | |
| 424 | | |
| 429 | | |
| 1,842 | | |
| -9 | | |
| -8 | | |
| -9 | | |
| -8 | |
Prevymis | |
| 174 | | |
| 188 | | |
| 362 | | |
| 129 | | |
| 143 | | |
| 273 | | |
| 157 | | |
| 175 | | |
| 605 | | |
| 31 | | |
| 35 | | |
| 33 | | |
| 37 | |
Dificid | |
| 73 | | |
| 92 | | |
| 165 | | |
| 65 | | |
| 76 | | |
| 141 | | |
| 74 | | |
| 87 | | |
| 302 | | |
| 20 | | |
| 20 | | |
| 16 | | |
| 16 | |
Zerbaxa | |
| 56 | | |
| 62 | | |
| 118 | | |
| 50 | | |
| 54 | | |
| 104 | | |
| 53 | | |
| 61 | | |
| 218 | | |
| 14 | | |
| 18 | | |
| 13 | | |
| 16 | |
Noxafil | |
| 56 | | |
| 45 | | |
| 101 | | |
| 60 | | |
| 55 | | |
| 116 | | |
| 51 | | |
| 46 | | |
| 213 | | |
| -20 | | |
| -9 | | |
| -13 | | |
| -2 | |
Cardiovascular | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Alliance
Revenue - Adempas/Verquvo (5) | |
| 98 | | |
| 106 | | |
| 203 | | |
| 99 | | |
| 68 | | |
| 167 | | |
| 92 | | |
| 108 | | |
| 367 | | |
| 56 | | |
| 56 | | |
| 22 | | |
| 22 | |
Adempas
(6) | |
| 70 | | |
| 72 | | |
| 142 | | |
| 59 | | |
| 65 | | |
| 125 | | |
| 65 | | |
| 66 | | |
| 255 | | |
| 11 | | |
| 15 | | |
| 14 | | |
| 17 | |
Winrevair | |
| | | |
| 70 | | |
| 70 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| - | | |
| - | | |
| - | |
Virology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Lagevrio | |
| 350 | | |
| 110 | | |
| 460 | | |
| 392 | | |
| 203 | | |
| 595 | | |
| 640 | | |
| 193 | | |
| 1,428 | | |
| -46 | | |
| -42 | | |
| -23 | | |
| -18 | |
Isentress/Isentress HD | |
| 111 | | |
| 89 | | |
| 200 | | |
| 123 | | |
| 136 | | |
| 259 | | |
| 119 | | |
| 105 | | |
| 483 | | |
| -35 | | |
| -31 | | |
| -23 | | |
| -19 | |
Delstrigo | |
| 56 | | |
| 60 | | |
| 116 | | |
| 44 | | |
| 50 | | |
| 94 | | |
| 54 | | |
| 54 | | |
| 201 | | |
| 19 | | |
| 23 | | |
| 23 | | |
| 26 | |
Pifeltro | |
| 42 | | |
| 39 | | |
| 81 | | |
| 34 | | |
| 38 | | |
| 72 | | |
| 37 | | |
| 33 | | |
| 142 | | |
| 3 | | |
| 4 | | |
| 13 | | |
| 13 | |
Neuroscience | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Belsomra | |
| 46 | | |
| 53 | | |
| 99 | | |
| 56 | | |
| 63 | | |
| 119 | | |
| 58 | | |
| 54 | | |
| 231 | | |
| -16 | | |
| -8 | | |
| -17 | | |
| -10 | |
Immunology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Simponi | |
| 184 | | |
| 172 | | |
| 356 | | |
| 180 | | |
| 180 | | |
| 359 | | |
| 179 | | |
| 171 | | |
| 710 | | |
| -4 | | |
| -2 | | |
| -1 | | |
| -1 | |
Remicade | |
| 39 | | |
| 35 | | |
| 74 | | |
| 51 | | |
| 48 | | |
| 99 | | |
| 45 | | |
| 43 | | |
| 187 | | |
| -27 | | |
| -20 | | |
| -25 | | |
| -21 | |
Diabetes
(7) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Januvia | |
| 419 | | |
| 405 | | |
| 824 | | |
| 551 | | |
| 511 | | |
| 1,062 | | |
| 581 | | |
| 547 | | |
| 2,189 | | |
| -21 | | |
| -16 | | |
| -22 | | |
| -19 | |
Janumet | |
| 251 | | |
| 224 | | |
| 475 | | |
| 329 | | |
| 354 | | |
| 683 | | |
| 255 | | |
| 240 | | |
| 1,177 | | |
| -37 | | |
| -32 | | |
| -30 | | |
| -26 | |
Other
Pharmaceutical (8) | |
| 576 | | |
| 573 | | |
| 1,151 | | |
| 626 | | |
| 560 | | |
| 1,187 | | |
| 568 | | |
| 576 | | |
| 2,333 | | |
| 2 | | |
| 6 | | |
| -3 | | |
| -1 | |
ANIMAL HEALTH | |
| 1,511 | | |
| 1,482 | | |
| 2,993 | | |
| 1,491 | | |
| 1,456 | | |
| 2,947 | | |
| 1,400 | | |
| 1,278 | | |
| 5,625 | | |
| 2 | | |
| 6 | | |
| 2 | | |
| 5 | |
Livestock | |
| 850 | | |
| 837 | | |
| 1,686 | | |
| 849 | | |
| 807 | | |
| 1,656 | | |
| 874 | | |
| 808 | | |
| 3,337 | | |
| 4 | | |
| 11 | | |
| 2 | | |
| 7 | |
Companion Animal | |
| 661 | | |
| 645 | | |
| 1,307 | | |
| 642 | | |
| 649 | | |
| 1,291 | | |
| 526 | | |
| 470 | | |
| 2,288 | | |
| -1 | | |
| 1 | | |
| 1 | | |
| 3 | |
Other
Revenues (9) | |
| 258 | | |
| 222 | | |
| 479 | | |
| 275 | | |
| 122 | | |
| 396 | | |
| 299 | | |
| 211 | | |
| 907 | | |
| 82 | | |
| 53 | | |
| 21 | | |
| 24 | |
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only
select products are shown.
(2) Alliance
Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance
Revenue represents royalties.
(4) Total
Vaccines sales were $3,424 million and $3,656 million in the first and second quarter of 2024, respectively, and $3,133 million and $3,557
million in the first and second quarter of 2023, respectively.
(5) Alliance
Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
(6) Net
product sales in Merck's marketing territories.
(7) Total
Diabetes sales were $745 million and $715 million in the first and second quarter of 2024, respectively, and $950 million and $951 million
in the first and second quarter of 2023, respectively.
(8) Includes
Pharmaceutical products not individually shown above.
(9) Other
Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61
million and $15 million in the first and second quarter of 2024, respectively, and $51 million and $3 million in the first and second
quarter of 2023, respectively.
Exhibit 99.2
MERCK
& CO., INC. |
CONSOLIDATED
STATEMENT OF OPERATIONS - GAAP |
(AMOUNTS
IN MILLIONS, EXCEPT PER SHARE FIGURES) |
(UNAUDITED) |
Table
1a |
| |
2024 | | |
2023 | | |
% Change | |
| |
1Q | | |
2Q | | |
June YTD | | |
1Q | | |
2Q | | |
June YTD | | |
3Q | | |
4Q | | |
Full Year | | |
2Q | | |
June YTD | |
Sales | |
$ | 15,775 | | |
$ | 16,112 | | |
$ | 31,887 | | |
$ | 14,487 | | |
$ | 15,035 | | |
$ | 29,522 | | |
$ | 15,962 | | |
$ | 14,630 | | |
$ | 60,115 | | |
| 7 | % | |
| 8 | % |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Costs, Expenses and Other | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
| 3,540 | | |
| 3,745 | | |
| 7,285 | | |
| 3,926 | | |
| 4,024 | | |
| 7,951 | | |
| 4,264 | | |
| 3,911 | | |
| 16,126 | | |
| -7 | % | |
| -8 | % |
Selling, general and administrative | |
| 2,483 | | |
| 2,739 | | |
| 5,221 | | |
| 2,479 | | |
| 2,702 | | |
| 5,182 | | |
| 2,519 | | |
| 2,804 | | |
| 10,504 | | |
| 1 | % | |
| 1 | % |
Research and development | |
| 3,992 | | |
| 3,500 | | |
| 7,492 | | |
| 4,276 | | |
| 13,321 | | |
| 17,597 | | |
| 3,307 | | |
| 9,628 | | |
| 30,531 | | |
| -74 | % | |
| -57 | % |
Restructuring costs | |
| 123 | | |
| 80 | | |
| 202 | | |
| 67 | | |
| 151 | | |
| 218 | | |
| 126 | | |
| 255 | | |
| 599 | | |
| -47 | % | |
| -7 | % |
Other (income) expense, net | |
| (33 | ) | |
| 42 | | |
| 12 | | |
| 89 | | |
| 172 | | |
| 259 | | |
| 126 | | |
| 78 | | |
| 466 | | |
| -76 | % | |
| -95 | % |
Income (Loss) Before Taxes | |
| 5,670 | | |
| 6,006 | | |
| 11,675 | | |
| 3,650 | | |
| (5,335 | ) | |
| (1,685 | ) | |
| 5,620 | | |
| (2,046 | ) | |
| 1,889 | | |
| * | | |
| * | |
Income Tax Provision (Benefit) | |
| 903 | | |
| 545 | | |
| 1,447 | | |
| 825 | | |
| 637 | | |
| 1,462 | | |
| 870 | | |
| (821 | ) | |
| 1,512 | | |
| | | |
| | |
Net Income (Loss) | |
| 4,767 | | |
| 5,461 | | |
| 10,228 | | |
| 2,825 | | |
| (5,972 | ) | |
| (3,147 | ) | |
| 4,750 | | |
| (1,225 | ) | |
| 377 | | |
| * | | |
| * | |
Less: Net Income Attributable to Noncontrolling Interests | |
| 5 | | |
| 6 | | |
| 11 | | |
| 4 | | |
| 3 | | |
| 7 | | |
| 5 | | |
| 1 | | |
| 12 | | |
| | | |
| | |
Net Income (Loss) Attributable to Merck & Co., Inc. | |
$ | 4,762 | | |
$ | 5,455 | | |
$ | 10,217 | | |
$ | 2,821 | | |
$ | (5,975 | ) | |
$ | (3,154 | ) | |
$ | 4,745 | | |
$ | (1,226 | ) | |
$ | 365 | | |
| * | | |
| * | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Earnings (Loss) per Common Share Assuming Dilution (1) | |
$ | 1.87 | | |
$ | 2.14 | | |
$ | 4.02 | | |
$ | 1.11 | | |
$ | (2.35 | ) | |
$ | (1.24 | ) | |
$ | 1.86 | | |
$ | (0.48 | ) | |
$ | 0.14 | | |
| * | | |
| * | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Average Shares Outstanding Assuming Dilution (1) | |
| 2,544 | | |
| 2,544 | | |
| 2,544 | | |
| 2,551 | | |
| 2,539 | | |
| 2,539 | | |
| 2,546 | | |
| 2,533 | | |
| 2,547 | | |
| | | |
| | |
Tax Rate | |
| 15.9 | % | |
| 9.1 | % | |
| 12.4 | % | |
| 22.6 | % | |
| -11.9 | % | |
| -86.8 | % | |
| 15.5 | % | |
| 40.1 | % | |
| 80.0 | % | |
| | | |
| | |
*
100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the company recorded a net loss in the second quarter and first six months of 2023, as well as the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.
MERCK &
CO., INC.
THREE
AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS
IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table
2b
| |
GAAP | | |
Acquisition and
Divestiture-Related
Costs (1) | | |
Restructuring
Costs (2) | | |
(Income)
Loss from
Investments
in Equity
Securities | | |
Certain
Other
Items | | |
Adjustment
Subtotal | | |
Non-GAAP | |
Second Quarter | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
$ | 4,024 | | |
| 467 | | |
| 32 | | |
| | | |
| | | |
| 499 | | |
$ | 3,525 | |
Selling, general and administrative | |
| 2,702 | | |
| 25 | | |
| 52 | | |
| | | |
| | | |
| 77 | | |
| 2,625 | |
Research and development | |
| 13,321 | | |
| 9 | | |
| 1 | | |
| | | |
| | | |
| 10 | | |
| 13,311 | |
Restructuring costs | |
| 151 | | |
| | | |
| 151 | | |
| | | |
| | | |
| 151 | | |
| - | |
Other (income) expense, net | |
| 172 | | |
| (3 | ) | |
| | | |
| 194 | | |
| | | |
| 191 | | |
| (19 | ) |
Loss Before Taxes | |
| (5,335 | ) | |
| (498 | ) | |
| (236 | ) | |
| (194 | ) | |
| | | |
| (928 | ) | |
| (4,407 | ) |
Income Tax Provision (Benefit) | |
| 637 | | |
| (91 | )(4) | |
| (38 | )(4) | |
| (44 | )(4) | |
| | | |
| (173 | ) | |
| 810 | |
Net Loss | |
| (5,972 | ) | |
| (407 | ) | |
| (198 | ) | |
| (150 | ) | |
| | | |
| (755 | ) | |
| (5,217 | ) |
Net Loss Attributable to Merck & Co., Inc. | |
| (5,975 | ) | |
| (407 | ) | |
| (198 | ) | |
| (150 | ) | |
| | | |
| (755 | ) | |
| (5,220 | ) |
Loss per Common Share Assuming Dilution(5) | |
$ | (2.35 | ) | |
| (0.16 | ) | |
| (0.07 | ) | |
| (0.06 | ) | |
| | | |
| (0.29 | ) | |
$ | (2.06 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Tax Rate | |
| -11.9 | % | |
| | | |
| | | |
| | | |
| | | |
| | | |
| -18.4 | % |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
June YTD | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
$ | 7,951 | | |
| 1,012 | | |
| 61 | | |
| | | |
| | | |
| 1,073 | | |
$ | 6,878 | |
Selling, general and administrative | |
| 5,182 | | |
| 45 | | |
| 53 | | |
| | | |
| | | |
| 98 | | |
| 5,084 | |
Research and development | |
| 17,597 | | |
| 19 | | |
| 1 | | |
| | | |
| | | |
| 20 | | |
| 17,577 | |
Restructuring costs | |
| 218 | | |
| | | |
| 218 | | |
| | | |
| | | |
| 218 | | |
| - | |
Other (income) expense, net | |
| 259 | | |
| 12 | | |
| | | |
| (235 | ) | |
| 573 | (3) | |
| 350 | | |
| (91 | ) |
(Loss) Income Before Taxes | |
| (1,685 | ) | |
| (1,088 | ) | |
| (333 | ) | |
| 235 | | |
| (573 | ) | |
| (1,759 | ) | |
| 74 | |
Income Tax Provision (Benefit) | |
| 1,462 | | |
| (196 | )(4) | |
| (56 | )(4) | |
| 51 | (4) | |
| (60 | )(4) | |
| (261 | ) | |
| 1,723 | |
Net Loss | |
| (3,147 | ) | |
| (892 | ) | |
| (277 | ) | |
| 184 | | |
| (513 | ) | |
| (1,498 | ) | |
| (1,649 | ) |
Net Loss Attributable to Merck & Co., Inc. | |
| (3,154 | ) | |
| (892 | ) | |
| (277 | ) | |
| 184 | | |
| (513 | ) | |
| (1,498 | ) | |
| (1,656 | ) |
Loss per Common Share Assuming Dilution(5) | |
$ | (1.24 | ) | |
| (0.35 | ) | |
| (0.11 | ) | |
| 0.07 | | |
| (0.20 | ) | |
| (0.59 | ) | |
$ | (0.65 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Tax Rate | |
| -86.8 | % | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 2,328.4 | % |
Only
the line items that are affected by non-GAAP adjustments are shown. |
|
Merck is providing certain
non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the
company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally
for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP
information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance
with GAAP. |
|
(1) Amounts
included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling,
general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts
included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts
included in other (income) expense, net, for the six-month period primarily reflect a $37 million loss on the sale of a business
and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination
of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income. |
(2) Amounts
primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related
to activities under the company's formal restructuring programs. |
(3) Reflects
a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. |
(4) Represents
the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP
adjustments. |
(5) Because
the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used
in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. |
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
| |
Global | | |
U.S. | | |
International | |
| |
2Q
2024 | | |
2Q
2023 | | |
%
Change | | |
2Q
2024 | | |
2Q
2023 | | |
%
Change | | |
2Q
2024 | | |
2Q
2023 | | |
%
Change | |
TOTAL
SALES (1) | |
$ | 16,112 | | |
$ | 15,035 | | |
| 7 | | |
$ | 7,876 | | |
$ | 7,018 | | |
| 12 | | |
$ | 8,236 | | |
$ | 8,018 | | |
| 3 | |
PHARMACEUTICAL | |
| 14,408 | | |
| 13,457 | | |
| 7 | | |
| 7,399 | | |
| 6,570 | | |
| 13 | | |
| 7,009 | | |
| 6,887 | | |
| 2 | |
Oncology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Keytruda | |
| 7,270 | | |
| 6,271 | | |
| 16 | | |
| 4,412 | | |
| 3,863 | | |
| 14 | | |
| 2,858 | | |
| 2,408 | | |
| 19 | |
Alliance
Revenue – Lynparza (2) | |
| 317 | | |
| 310 | | |
| 2 | | |
| 153 | | |
| 144 | | |
| 6 | | |
| 165 | | |
| 166 | | |
| -1 | |
Alliance
Revenue – Lenvima (2) | |
| 249 | | |
| 242 | | |
| 3 | | |
| 177 | | |
| 163 | | |
| 8 | | |
| 73 | | |
| 79 | | |
| -7 | |
Welireg | |
| 126 | | |
| 50 | | |
| 150 | | |
| 116 | | |
| 49 | | |
| 138 | | |
| 10 | | |
| 2 | | |
| * | |
Alliance
Revenue – Reblozyl (3) | |
| 90 | | |
| 47 | | |
| 92 | | |
| 75 | | |
| 36 | | |
| 110 | | |
| 15 | | |
| 11 | | |
| 36 | |
Vaccines
(4) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gardasil / Gardasil 9 | |
| 2,478 | | |
| 2,458 | | |
| 1 | | |
| 536 | | |
| 464 | | |
| 16 | | |
| 1,941 | | |
| 1,994 | | |
| -3 | |
ProQuad / M-M-R II/Varivax | |
| 617 | | |
| 582 | | |
| 6 | | |
| 490 | | |
| 447 | | |
| 10 | | |
| 127 | | |
| 135 | | |
| -6 | |
Vaxneuvance | |
| 189 | | |
| 168 | | |
| 13 | | |
| 99 | | |
| 147 | | |
| -33 | | |
| 90 | | |
| 20 | | |
| * | |
RotaTeq | |
| 163 | | |
| 131 | | |
| 25 | | |
| 107 | | |
| 93 | | |
| 15 | | |
| 56 | | |
| 37 | | |
| 50 | |
Pneumovax 23 | |
| 59 | | |
| 92 | | |
| -36 | | |
| 11 | | |
| 23 | | |
| -54 | | |
| 48 | | |
| 69 | | |
| -30 | |
Hospital Acute Care | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Bridion | |
| 455 | | |
| 502 | | |
| -9 | | |
| 351 | | |
| 299 | | |
| 17 | | |
| 104 | | |
| 203 | | |
| -49 | |
Prevymis | |
| 188 | | |
| 143 | | |
| 31 | | |
| 90 | | |
| 61 | | |
| 47 | | |
| 98 | | |
| 82 | | |
| 19 | |
Dificid | |
| 92 | | |
| 76 | | |
| 20 | | |
| 79 | | |
| 68 | | |
| 16 | | |
| 12 | | |
| 8 | | |
| 56 | |
Zerbaxa | |
| 62 | | |
| 54 | | |
| 14 | | |
| 33 | | |
| 30 | | |
| 12 | | |
| 28 | | |
| 24 | | |
| 17 | |
Noxafil | |
| 45 | | |
| 55 | | |
| -20 | | |
| | | |
| 11 | | |
| N/M | | |
| 44 | | |
| 45 | | |
| -1 | |
Cardiovascular | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Alliance
Revenue - Adempas/Verquvo (5) | |
| 106 | | |
| 68 | | |
| 56 | | |
| 98 | | |
| 70 | | |
| 41 | | |
| 8 | | |
| -2 | | |
| * | |
Adempas
(6) | |
| 72 | | |
| 65 | | |
| 11 | | |
| | | |
| | | |
| | | |
| 72 | | |
| 65 | | |
| 11 | |
Winrevair | |
| 70 | | |
| | | |
| - | | |
| 70 | | |
| | | |
| - | | |
| | | |
| | | |
| | |
Virology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Lagevrio | |
| 110 | | |
| 203 | | |
| -46 | | |
| 15 | | |
| 2 | | |
| * | | |
| 95 | | |
| 201 | | |
| -53 | |
Isentress/Isentress HD | |
| 89 | | |
| 136 | | |
| -35 | | |
| 43 | | |
| 56 | | |
| -24 | | |
| 46 | | |
| 80 | | |
| -42 | |
Delstrigo | |
| 60 | | |
| 50 | | |
| 19 | | |
| 14 | | |
| 13 | | |
| 13 | | |
| 45 | | |
| 37 | | |
| 21 | |
Pifeltro | |
| 39 | | |
| 38 | | |
| 3 | | |
| 27 | | |
| 27 | | |
| -1 | | |
| 12 | | |
| 11 | | |
| 15 | |
Neuroscience | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Belsomra | |
| 53 | | |
| 63 | | |
| -16 | | |
| 19 | | |
| 21 | | |
| -12 | | |
| 34 | | |
| 42 | | |
| -18 | |
Immunology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Simponi | |
| 172 | | |
| 180 | | |
| -4 | | |
| | | |
| | | |
| | | |
| 172 | | |
| 180 | | |
| -4 | |
Remicade | |
| 35 | | |
| 48 | | |
| -27 | | |
| | | |
| | | |
| | | |
| 35 | | |
| 48 | | |
| -27 | |
Diabetes
(7) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Januvia | |
| 405 | | |
| 511 | | |
| -21 | | |
| 177 | | |
| 243 | | |
| -27 | | |
| 227 | | |
| 267 | | |
| -15 | |
Janumet | |
| 224 | | |
| 354 | | |
| -37 | | |
| 17 | | |
| 82 | | |
| -80 | | |
| 208 | | |
| 272 | | |
| -24 | |
Other
Pharmaceutical (8) | |
| 573 | | |
| 560 | | |
| 2 | | |
| 190 | | |
| 158 | | |
| 20 | | |
| 386 | | |
| 403 | | |
| -4 | |
ANIMAL HEALTH | |
| 1,482 | | |
| 1,456 | | |
| 2 | | |
| 455 | | |
| 475 | | |
| -4 | | |
| 1,027 | | |
| 982 | | |
| 5 | |
Livestock | |
| 837 | | |
| 807 | | |
| 4 | | |
| 168 | | |
| 165 | | |
| 2 | | |
| 669 | | |
| 643 | | |
| 4 | |
Companion Animal | |
| 645 | | |
| 649 | | |
| -1 | | |
| 287 | | |
| 310 | | |
| -7 | | |
| 358 | | |
| 339 | | |
| 6 | |
Other
Revenues (9) | |
| 222 | | |
| 122 | | |
| 82 | | |
| 22 | | |
| -27 | | |
| -181 | | |
| 200 | | |
| 149 | | |
| 34 | |
*200%
or greater |
N/M
- Not Meaningful |
Sum
of U.S. plus international may not equal global due to rounding. |
(1) Only
select products are shown. |
(2) Alliance
Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. |
(3) Alliance
Revenue represents royalties. |
(4) Total
Vaccines sales were $3,656 million in the second quarter of 2024 and $3,557 million in the second quarter of 2023. |
(5) Alliance
Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs. |
(6) Net
product sales in Merck's marketing territories. |
(7) Total
Diabetes sales were $715 million in the second quarter of 2024, and $951 million in the second quarter of 2023. |
(8) Includes
Pharmaceutical products not individually shown above. |
(9) Other
Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$15 million in the second quarter of 2024 and $3 million in the second quarter of 2023. |
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
| |
Global | | |
U.S. | | |
International | |
| |
June YTD
2024 | | |
June YTD
2023 | | |
% Change | | |
June YTD
2024 | | |
June YTD
2023 | | |
% Change | | |
June YTD
2024 | | |
June YTD
2023 | | |
% Change | |
TOTAL SALES (1) | |
$ | 31,887 | | |
$ | 29,522 | | |
| 8 | | |
$ | 15,354 | | |
$ | 13,676 | | |
| 12 | | |
$ | 16,533 | | |
$ | 15,846 | | |
| 4 | |
PHARMACEUTICAL | |
| 28,415 | | |
| 26,179 | | |
| 9 | | |
| 14,336 | | |
| 12,688 | | |
| 13 | | |
| 14,079 | | |
| 13,491 | | |
| 4 | |
Oncology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Keytruda | |
| 14,217 | | |
| 12,065 | | |
| 18 | | |
| 8,531 | | |
| 7,348 | | |
| 16 | | |
| 5,686 | | |
| 4,718 | | |
| 21 | |
Alliance Revenue – Lynparza (2) | |
| 609 | | |
| 585 | | |
| 4 | | |
| 288 | | |
| 286 | | |
| 1 | | |
| 321 | | |
| 299 | | |
| 7 | |
Alliance Revenue – Lenvima (2) | |
| 504 | | |
| 474 | | |
| 6 | | |
| 349 | | |
| 316 | | |
| 10 | | |
| 155 | | |
| 158 | | |
| -2 | |
Welireg | |
| 211 | | |
| 92 | | |
| 128 | | |
| 194 | | |
| 90 | | |
| 116 | | |
| 17 | | |
| 3 | | |
| * | |
Alliance Revenue – Reblozyl (3) | |
| 161 | | |
| 90 | | |
| 80 | | |
| 133 | | |
| 66 | | |
| 102 | | |
| 28 | | |
| 24 | | |
| 17 | |
Vaccines (4) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gardasil/Gardasil 9 | |
| 4,727 | | |
| 4,430 | | |
| 7 | | |
| 1,024 | | |
| 880 | | |
| 16 | | |
| 3,702 | | |
| 3,550 | | |
| 4 | |
ProQuad/M-M-R II/Varivax | |
| 1,187 | | |
| 1,109 | | |
| 7 | | |
| 928 | | |
| 868 | | |
| 7 | | |
| 259 | | |
| 242 | | |
| 7 | |
Vaxneuvance | |
| 408 | | |
| 274 | | |
| 49 | | |
| 260 | | |
| 241 | | |
| 8 | | |
| 148 | | |
| 33 | | |
| * | |
RotaTeq | |
| 379 | | |
| 428 | | |
| -11 | | |
| 257 | | |
| 273 | | |
| -6 | | |
| 123 | | |
| 155 | | |
| -21 | |
Pneumovax 23 | |
| 120 | | |
| 188 | | |
| -36 | | |
| 17 | | |
| 63 | | |
| -73 | | |
| 103 | | |
| 125 | | |
| -17 | |
Hospital Acute Care | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Bridion | |
| 895 | | |
| 989 | | |
| -9 | | |
| 680 | | |
| 576 | | |
| 18 | | |
| 215 | | |
| 413 | | |
| -48 | |
Prevymis | |
| 362 | | |
| 273 | | |
| 33 | | |
| 165 | | |
| 116 | | |
| 42 | | |
| 197 | | |
| 157 | | |
| 26 | |
Dificid | |
| 165 | | |
| 141 | | |
| 16 | | |
| 147 | | |
| 130 | | |
| 13 | | |
| 17 | | |
| 11 | | |
| 54 | |
Zerbaxa | |
| 118 | | |
| 104 | | |
| 13 | | |
| 67 | | |
| 57 | | |
| 17 | | |
| 51 | | |
| 47 | | |
| 9 | |
Noxafil | |
| 101 | | |
| 116 | | |
| -13 | | |
| 8 | | |
| 25 | | |
| -67 | | |
| 92 | | |
| 91 | | |
| 2 | |
Cardiovascular | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Alliance Revenue - Adempas/Verquvo (5) | |
| 203 | | |
| 167 | | |
| 22 | | |
| 188 | | |
| 153 | | |
| 23 | | |
| 16 | | |
| 14 | | |
| 11 | |
Adempas (6) | |
| 142 | | |
| 125 | | |
| 14 | | |
| | | |
| | | |
| | | |
| 142 | | |
| 125 | | |
| 14 | |
Winrevair | |
| 70 | | |
| | | |
| - | | |
| 70 | | |
| | | |
| - | | |
| | | |
| | | |
| | |
Virology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Lagevrio | |
| 460 | | |
| 595 | | |
| -23 | | |
| 60 | | |
| | | |
| - | | |
| 400 | | |
| 595 | | |
| -33 | |
Isentress/Isentress HD | |
| 200 | | |
| 259 | | |
| -23 | | |
| 93 | | |
| 108 | | |
| -14 | | |
| 107 | | |
| 151 | | |
| -29 | |
Delstrigo | |
| 116 | | |
| 94 | | |
| 23 | | |
| 26 | | |
| 24 | | |
| 11 | | |
| 89 | | |
| 70 | | |
| 27 | |
Pifeltro | |
| 81 | | |
| 72 | | |
| 13 | | |
| 56 | | |
| 51 | | |
| 9 | | |
| 25 | | |
| 21 | | |
| 20 | |
Neuroscience | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Belsomra | |
| 99 | | |
| 119 | | |
| -17 | | |
| 33 | | |
| 37 | | |
| -10 | | |
| 66 | | |
| 82 | | |
| -19 | |
Immunology | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Simponi | |
| 356 | | |
| 359 | | |
| -1 | | |
| | | |
| | | |
| | | |
| 356 | | |
| 359 | | |
| -1 | |
Remicade | |
| 74 | | |
| 99 | | |
| -25 | | |
| | | |
| | | |
| | | |
| 74 | | |
| 99 | | |
| -25 | |
Diabetes (7) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Januvia | |
| 824 | | |
| 1,062 | | |
| -22 | | |
| 361 | | |
| 514 | | |
| -30 | | |
| 463 | | |
| 548 | | |
| -15 | |
Janumet | |
| 475 | | |
| 683 | | |
| -30 | | |
| 55 | | |
| 138 | | |
| -60 | | |
| 420 | | |
| 544 | | |
| -23 | |
Other Pharmaceutical (8) | |
| 1,151 | | |
| 1,187 | | |
| -3 | | |
| 346 | | |
| 328 | | |
| 5 | | |
| 807 | | |
| 857 | | |
| -6 | |
ANIMAL HEALTH | |
| 2,993 | | |
| 2,947 | | |
| 2 | | |
| 929 | | |
| 956 | | |
| -3 | | |
| 2,064 | | |
| 1,991 | | |
| 4 | |
Livestock | |
| 1,686 | | |
| 1,656 | | |
| 2 | | |
| 334 | | |
| 338 | | |
| -1 | | |
| 1,352 | | |
| 1,318 | | |
| 3 | |
Companion Animal | |
| 1,307 | | |
| 1,291 | | |
| 1 | | |
| 595 | | |
| 618 | | |
| -4 | | |
| 712 | | |
| 673 | | |
| 6 | |
Other Revenues (9) | |
| 479 | | |
| 396 | | |
| 21 | | |
| 89 | | |
| 32 | | |
| 178 | | |
| 390 | | |
| 364 | | |
| 7 | |
*200%
or greater |
Sum
of U.S. plus international may not equal global due to rounding. |
|
(1) Only
select products are shown. |
(2) Alliance
Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. |
(3) Alliance
Revenue represents royalties. |
(4) Total
Vaccines sales were $7,080 million and $6,690 million on a global basis for June YTD 2024 and 2023, respectively. |
(5) Alliance
Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs. |
(6) Net
product sales in Merck's marketing territories. |
(7) Total
Diabetes sales were $1,461 million and $1,901 million on a global basis for June YTD 2024 and 2023, respectively. |
(8) Includes
Pharmaceutical products not individually shown above. |
(9) Other
Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$76 million and $54 million on a global basis for June YTD 2024 and 2023, respectively. |
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
| |
2024 | | |
2023 | | |
%
Change | |
| |
1Q | | |
2Q | | |
June YTD | | |
1Q | | |
2Q | | |
June YTD | | |
3Q | | |
4Q | | |
Full
Year | | |
2Q | | |
June YTD | |
TOTAL
PHARMACEUTICAL | |
$ | 14,006 | | |
$ | 14,408 | | |
$ | 28,415 | | |
$ | 12,721 | | |
$ | 13,457 | | |
$ | 26,179 | | |
$ | 14,263 | | |
$ | 13,141 | | |
$ | 53,583 | | |
| 7 | | |
| 9 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
United States | |
| 6,936 | | |
| 7,399 | | |
| 14,336 | | |
| 6,117 | | |
| 6,570 | | |
| 12,688 | | |
| 7,153 | | |
| 6,698 | | |
| 26,539 | | |
| 13 | | |
| 13 | |
% Pharmaceutical
Sales | |
| 49.5 | % | |
| 51.4 | % | |
| 50.5 | % | |
| 48.1 | % | |
| 48.8 | % | |
| 48.5 | % | |
| 50.1 | % | |
| 51.0 | % | |
| 49.5 | % | |
| | | |
| | |
Europe
(1) | |
| 2,555 | | |
| 2,572 | | |
| 5,128 | | |
| 2,326 | | |
| 2,401 | | |
| 4,727 | | |
| 2,497 | | |
| 2,491 | | |
| 9,715 | | |
| 7 | | |
| 8 | |
% Pharmaceutical
Sales | |
| 18.2 | % | |
| 17.9 | % | |
| 18.0 | % | |
| 18.3 | % | |
| 17.8 | % | |
| 18.1 | % | |
| 17.5 | % | |
| 19.0 | % | |
| 18.1 | % | |
| | | |
| | |
China | |
| 1,744 | | |
| 1,790 | | |
| 3,534 | | |
| 1,694 | | |
| 1,887 | | |
| 3,581 | | |
| 1,674 | | |
| 1,456 | | |
| 6,710 | | |
| -5 | | |
| -1 | |
% Pharmaceutical
Sales | |
| 12.5 | % | |
| 12.4 | % | |
| 12.4 | % | |
| 13.3 | % | |
| 14.0 | % | |
| 13.7 | % | |
| 11.7 | % | |
| 11.1 | % | |
| 12.5 | % | |
| | | |
| | |
Japan | |
| 802 | | |
| 664 | | |
| 1,466 | | |
| 737 | | |
| 652 | | |
| 1,390 | | |
| 1,062 | | |
| 629 | | |
| 3,081 | | |
| 2 | | |
| 6 | |
% Pharmaceutical
Sales | |
| 5.7 | % | |
| 4.6 | % | |
| 5.2 | % | |
| 5.8 | % | |
| 4.8 | % | |
| 5.3 | % | |
| 7.4 | % | |
| 4.8 | % | |
| 5.7 | % | |
| | | |
| | |
Latin America | |
| 601 | | |
| 661 | | |
| 1,262 | | |
| 470 | | |
| 566 | | |
| 1,036 | | |
| 696 | | |
| 596 | | |
| 2,328 | | |
| 17 | | |
| 22 | |
% Pharmaceutical
Sales | |
| 4.3 | % | |
| 4.6 | % | |
| 4.4 | % | |
| 3.7 | % | |
| 4.2 | % | |
| 4.0 | % | |
| 4.9 | % | |
| 4.5 | % | |
| 4.3 | % | |
| | | |
| | |
Asia Pacific (other than
China and Japan) | |
| 580 | | |
| 595 | | |
| 1,175 | | |
| 703 | | |
| 705 | | |
| 1,409 | | |
| 636 | | |
| 616 | | |
| 2,661 | | |
| -16 | | |
| -17 | |
% Pharmaceutical
Sales | |
| 4.1 | % | |
| 4.1 | % | |
| 4.1 | % | |
| 5.5 | % | |
| 5.2 | % | |
| 5.4 | % | |
| 4.5 | % | |
| 4.7 | % | |
| 5.0 | % | |
| | | |
| | |
Eastern Europe/Middle East/Africa | |
| 395 | | |
| 353 | | |
| 747 | | |
| 381 | | |
| 370 | | |
| 751 | | |
| 301 | | |
| 299 | | |
| 1,351 | | |
| -5 | | |
| -1 | |
% Pharmaceutical
Sales | |
| 2.8 | % | |
| 2.4 | % | |
| 2.6 | % | |
| 3.0 | % | |
| 2.7 | % | |
| 2.9 | % | |
| 2.1 | % | |
| 2.3 | % | |
| 2.5 | % | |
| | | |
| | |
Canada | |
| 138 | | |
| 143 | | |
| 281 | | |
| 141 | | |
| 127 | | |
| 268 | | |
| 133 | | |
| 138 | | |
| 540 | | |
| 12 | | |
| 5 | |
% Pharmaceutical
Sales | |
| 1.0 | % | |
| 1.0 | % | |
| 1.0 | % | |
| 1.1 | % | |
| 0.9 | % | |
| 1.0 | % | |
| 0.9 | % | |
| 1.1 | % | |
| 1.0 | % | |
| | | |
| | |
Other | |
| 255 | | |
| 231 | | |
| 486 | | |
| 152 | | |
| 179 | | |
| 329 | | |
| 111 | | |
| 218 | | |
| 658 | | |
| 29 | | |
| 48 | |
%
Pharmaceutical Sales | |
| 1.9 | % | |
| 1.6 | % | |
| 1.8 | % | |
| 1.2 | % | |
| 1.6 | % | |
| 1.1 | % | |
| 0.9 | % | |
| 1.5 | % | |
| 1.4 | % | |
| | | |
| | |
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
OTHER
(INCOME) EXPENSE, NET |
|
|
|
|
|
| |
2Q24 | | |
2Q23 | | |
June
YTD
2024 | | |
June
YTD
2023 | |
Interest income | |
$ | (69 | ) | |
$ | (109 | ) | |
$ | (141 | ) | |
$ | (221 | ) |
Interest expense | |
| 310 | | |
| 277 | | |
| 613 | | |
| 519 | |
Exchange losses | |
| 60 | | |
| 62 | | |
| 144 | | |
| 122 | |
(Income) loss from investments in equity securities, net (1) | |
| (56 | ) | |
| 175 | | |
| (200 | ) | |
| (274 | ) |
Net periodic defined benefit plan (credit) cost other than service cost | |
| (159 | ) | |
| (111 | ) | |
| (319 | ) | |
| (226 | ) |
Other, net | |
| (44 | ) | |
| (122 | ) | |
| (85 | ) | |
| 339 | |
Total | |
$ | 42 | | |
$ | 172 | | |
$ | 12 | | |
$ | 259 | |
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
v3.24.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec0.500NotesDue2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec1.875NotesDue2026Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec3.250NotesDue2032Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec2.500NotesDue2034Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec1.375NotesDue2036Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec3.500NotesDue2037Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec3.700NotesDue2044Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=mrk_Sec3.750NotesDue2054Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Merck (NYSE:MRK)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2023 bis Aug 2024